Experimental hair loss pill just cleared a major hurdle — when it could hit shelves
A Connecticut-based biopharmaceutical company, Veradermics, has reported positive results from a clinical trial of its experimental oral hair loss treatment, VDPHL01, which uses a higher dose of minoxidil. Men taking the pill grew 30 to 33 more hairs per square centimeter over six months compared to seven in the placebo group, with no reported cardiac side effects. The treatment aims to become the first FDA-approved non-hormonal oral therapy for pattern hair loss, with further trials ongoing for both men and women.
- ▪Men in the trial grew 30 to 33 more hairs per square centimeter after six months on VDPHL01, compared to seven in the placebo group.
- ▪VDPHL01 contains 8.5 milligrams of minoxidil, nearly twice the maximum recommended daily dose of 5 milligrams.
- ▪No treatment-related cardiac issues were reported in the 519-participant trial, though 6% experienced peripheral edema.
- ▪79% to 86% of participants on the pill reported hair improvement after six months, compared to 35% on placebo.
- ▪Veradermics is conducting trials for both male and female pattern hair loss and has not yet finalized the optimal dosing regimen.
Opening excerpt (first ~120 words) tap to expand
Men's Health Experimental hair loss pill just cleared a major hurdle — when it could hit shelves By Tracy Swartz Published May 5, 2026, 6:00 a.m. ET It’s not something to brush off. Hair loss is a widespread problem in the US, with roughly 50 million men and 30 million women experiencing pattern baldness. No special potion completely reverses genetic or age-related decline, but there are a few products that seem to halt further loss, thicken existing hair and promote regrowth. Now, a Connecticut-based biopharmaceutical company is sharing promising results of its experimental treatment, which is a revved-up spin on the active ingredient in Rogaine.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at New York Post.
Discussion
0 commentsMore from New York Post
